5:30 AM
Dec 05, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Non-alcoholic steatohepatitis (NASH)

Patient sample and mouse studies suggest inhibiting the Notch pathway components HES1, γ secretase, MAML1 and NCSTN could help treat NASH. In NASH patient liver tissue samples, hepatocyte levels of HES1 were higher than in samples from patients with simple steatosis or healthy volunteers. In a mouse model...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >